Clever Leaves Holdings Begins Sales of Cannabis Extracts in Germany Through Ethypharm Partnership

Clever Leaves Holdings Begins Sales of Cannabis Extracts in Germany Through Ethypharm Partnership

Products imported and to be commercially available in German

BOCA RATON, Fla., Feb. 17, 2022 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc.
(NASDAQ: CLVR, CLVRW) (“Clever Leaves Holdings” or the “Company”), a leading
multinational operator and licensed producer of pharmaceutical-grade cannabinoids, today
announced the importation of its first German high-quality standards compliant commercial
extracts that will soon be available for distribution by its partner in Germany Ethypharm
GmbH (“Ethypharm”), a European specialty pharmaceutical company.
We are one of the first to successfully complete a commercial shipment of Colombianmanufactured
high-CBD pharmaceutical product to Germany available for patients in
pharmacies under prescription.
Following a March 2021 supply agreement signed by the two companies providing
Ethypharm access to Clever Leaves Holdings EU GMP certified cannabis extracts, the
shipment includes two products: a 100 mg CBD with 3 mg THC per gram formulation and a
200 mg CBD with 6 mg THC per gram formulation. Partnering with an established
pharmaceutical company like Ethypharm allows Clever Leaves Holdings to enter the
German pharmaceutical market more broadly, which may accelerate the Company’s
expansion into the gradually expanding European cannabis market.
“As the largest medical cannabis market in Europe and one of the most demanding from a
pharma-quality perspective, Germany has become one of the most important markets to us.
This importation illustrates the ability of the Clever Leaves Holding team to manufacture EUGMP
and German Pharmacopoeia compliant products and provide pharmaceutical clients
with an asset-light path to market. In addition, this reflects our increasing know-how to
comply with complex and sophisticated regulatory and quality frameworks. This is especially
relevant in an environment of constantly changing cannabis legislation across different
countries,” explained Andrés Fajardo, President of Clever Leaves Holdings. “Partnering with
a pharmaceutical leader like Ethypharm enhances our distribution by aligning with an
organization which specializes and excels at the marketing and distribution of prescribed
pharmaceutical products in Germany”, he added.
“Ethypharm aspires to work closely with doctors and pharmacists to improve patients’ lives.
The medicinal cannabis extracts we are now launching in Germany address patients’ needs,
especially those

For further information, please contact:

SENSO Communications
Penny Lukats, 07775992350,

For more information on the EUMCA ( and membership, please contact:
Sita Schubert, General Secretary of the EUMCA on +32 233 90 281,



The EUMCA is the first international non-profit association governed by the provisions of the Belgian Code des Sociétés et des Associations. Its membership is a multi-stakeholder network representing the interests of a wide range of organisations operating in the research and development, production and/or distribution of medical cannabis-based treatments.

The EUMCA’s mission is to improve the life and health outcomes of patients across Europe, by promoting the development of national government healthcare policies that advocate i) the ethical prescription of pharmaceutical-grade medicinal cannabis, and ii) advance patient access to treatments. It does this through:

  • Research & Development: Promoting scientific medical research and policy to support the standardised, ethical and sustainable use of medicinal cannabis.
  • Patient Access & Reimbursement: Working with national reimbursement institutions to improve patient access to medical cannabis-based treatments.
  • Medical Education: Providing evidence-based knowledge and learning on medicinal cannabis to healthcare professionals and patients.
  • Legal & Compliance: Consulting with governments where ongoing or urgent action is necessary.
  • Regulatory & Quality: Providing members with counsel and guidance on regulatory affairs.
  • Business Development: Delivering networking opportunities for members focused on building their business through M&A, licensing, partnering and novel in-market strategies.